PTCT Earnings
PTC Therapeutics Inc
$
46.710
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of PTC Therapeutics Inc(PTCT) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of PTC Therapeutics Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2025Q2 | 2025-08-07 | After Hours | -1.07 | -0.83 | +22.43 | 174.03M | 178.88M | +2.78 | -9.89 | - |
| FY2025Q1 | 2025-05-06 | After Hours | -1.08 | 10.04 | +1029.63 | 372.61M | 1.18B | +215.64 | +12.63 | +27.13 |
| FY2024Q4 | 2025-02-27 | After Hours | -0.96 | -0.85 | +11.46 | 248.99M | 213.17M | -14.39 | +9.27 | +4.41 |
| FY2024Q2 | 2024-08-08 | After Hours | -1.00 | -1.29 | +29.00 | 181.01M | 186.70M | +3.14 | -3.57 | +1.82 |
| FY2024Q1 | 2024-04-25 | - | -1.21 | -1.20 | +0.83 | 163.82M | 210.12M | +28.26 | +1.11 | +35.50 |
| FY2023Q4 | 2024-02-29 | - | 0.29 | -0.24 | -182.76 | 318.33M | 307.06M | -3.54 | -0.04 | +9.50 |
| FY2023Q3 | 2023-10-26 | - | -0.85 | -1.76 | -107.06 | 211.72M | 196.58M | -7.15 | +2.88 | -20.75 |
| FY2023Q2 | 2023-08-03 | - | -1.58 | -2.66 | -68.35 | 205.94M | 213.81M | +3.82 | +0.30 | -0.87 |
| - | 2023-04-27 | - | -1.64 | -1.88 | -14.63 | - | - | - | +0.77 | +6.07 |
| - | 2023-02-21 | - | -1.96 | -2.35 | -19.90 | - | - | - | -4.20 | -9.62 |
PTCT Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, PTC Therapeutics Inc reported performance for FY2025Q2, announced on 2025-08-07. The company achieved an EPS of -0.83, compared to analyst estimates of -1.07 by 22.43% . Revenue for the quarter reached 178.88M compared to expectations of 174.03M by 2.78% .
The stock price reacted with a -9.89% one-day change and a % five-day change following the earnings release. These movements reflect market reaction in PTC Therapeutics Inc growth trajectory and strategic initiatives.
PTCT Earnings Forecast
Looking ahead, PTC Therapeutics Inc(PTCT) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q3 project quarter revenue of 188.13M and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 8.83%, while EPS estimates have been Revise Downward by -3.62%. For the upcoming , revenue estimates have been adjusted Go Up by 0.69% . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in PTC Therapeutics Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between PTCT's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+8.83%
In Past 3 Month
Revenue Estimates for Q3 2025
Revise Downward
-3.62%
In Past 3 Month
Stock Price
Go Up
+0.69%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:1.63B
--
EPS Estimate-Annual FY 2025:0
—
Stock Price46.71
PTCT Revenue and EPS Performance: A Historical Perspective
PTC Therapeutics Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q2 (2025-08-07,After Hours):
EPS: -0.83 (Actual) vs.-1.07 (Estimate) (22.43%)
Revenue: 178.88M (Actual) vs. 174.03M (Estimate) (2.78%)
Price Reaction: -9.89%(1-Day), %(5-Day)
FY2025Q1 (2025-05-06,After Hours):
EPS: 10.04 (Actual) vs.-1.08 (Estimate) (1029.63%)
Revenue: 1.18B (Actual) vs. 372.61M (Estimate) (215.64%)
Price Reaction: 12.63%(1-Day), 27.13%(5-Day)
FY2024Q4 (2025-02-27,After Hours):
EPS: -0.85 (Actual) vs.-0.96 (Estimate) (11.46%)
Revenue: 213.17M (Actual) vs. 248.99M (Estimate) (-14.39%)
Price Reaction: 9.27%(1-Day), 4.41%(5-Day)
Earnings Reaction
The chart below shows how PTCT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PTCT sees a +0.17% change in stock price 10 days leading up to the earnings, and a +4.21% change 10 days following the report. On the earnings day itself, the stock moves by -1.10%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in JUN/2025, the stock changed -9.89% on the day following the earnings release and then changed by -7.25% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
PTC Therapeutics Inc (PTCT) Q2 2025 Earnings Call Summary
Positive
2025-08-08
The earnings call summary highlights strong financial health, positive product development, and strategic market plans. The Q&A section reveals positive sentiment from analysts, especially regarding new product launches and partnerships. Despite some uncertainties, the overall outlook is optimistic, with strong revenue potential and effective cost management. The market cap suggests moderate sensitivity, leading to a positive stock price prediction.
PTC Therapeutics Inc (PTCT) Q1 2025 Earnings Call Summary
Positive
2025-05-06
The earnings call indicates strong financial performance with increased revenue and a robust cash position. Positive developments include the collaboration with Novartis and anticipated revenue from SUFIANCE in Europe. Despite macro uncertainties, the company's strategic plans and new product launches are promising. The Q&A highlights confidence in regulatory progress and market access strategies. However, the lack of a shareholder return plan and unclear management responses introduce some risk. Given the company's market cap, these factors suggest a positive stock price movement in the near term.
PTC Therapeutics Inc (PTCT) Q4 2024 Earnings Call Summary
Neutral
2025-02-27
The company's strong revenue growth and cash position are positive, but lack of shareholder return plans and potential regulatory risks introduce uncertainty. The Q&A highlights some optimism about market opportunities and payers' willingness to support treatments, yet management's unclear responses on key financial metrics and strategic plans add caution. Given the medium market cap, the stock price is likely to remain stable, reflecting a balanced view of positive financial performance and operational challenges.
PTC Therapeutics, Inc. (PTCT) Q3 2024 Earnings Call Summary
Positive
2024-11-08
The earnings call highlights strong financial performance with increased total revenue and a solid cash position. The potential revenue from Sepiapterin and the upcoming Vatiquinone launch provide positive future prospects. The Q&A session revealed excitement from providers about new therapies and expectations of strong future revenue, despite some concerns about European sales and unclear FDA meeting outcomes. Overall, the positive financials and optimistic product outlook suggest a likely positive stock price movement.
People Also Watch
ATHM
Autohome Inc
29.500
USD
+2.61%
RYTM
Rhythm Pharmaceuticals Inc
98.180
USD
+1.78%
SNEX
StoneX Group Inc
92.360
USD
-0.11%
ASH
Ashland Inc
54.410
USD
+2.49%
CNXC
Concentrix Corp
48.470
USD
+4.51%
AMBA
Ambarella Inc
69.190
USD
+0.03%
FORM
FormFactor Inc
30.100
USD
+0.94%
DLO
Dlocal Ltd
11.328
USD
+3.25%
REZI
Resideo Technologies Inc
31.920
USD
+2.05%
STR
Sitio Royalties Corp
18.580
USD
-0.32%
FAQ
What were the key highlights of PTCT’s latest earnings report for FY2025Q2?
PTCT reported its FY2025Q2 earnings on 2025-08-07, showcasing a revenue of 178.88M against an estimate of 174.03M, resulting in a 2.78% surprise. The EPS was -0.83, surpassing the expected -1.07 by 22.43% . The stock experienced a -9.89% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.
How did PTCT’s stock price react after the FY2025Q2 earnings release?
What are the revenue and EPS estimates for PTCT for 2025/Q3?
How does PTCT’s stock price correlate with earnings forecast revisions?
What should investors expect from PTCT’s next earnings report?